Low-Dose Peptide Tolerance Therapy of Lupus Generates Plasmacytoid Dendritic Cells That Cause Expansion of
T olerance therapy for systemic lupus erythematosus using autoantigenic peptides that specifically target pathogenic autoimmune cells is a highly desirable goal (1) (2) (3) (4) (5) . Due to intrinsic defects in lupus immune system, nucleosomes from apoptotic cells become major immunogens initiating cognate interactions between autoimmune CD4
ϩ Th cells and B cells leading to production of somatically mutated, class-switched autoantibodies that form pathogenic immune complexes with diverse nuclear Ags (6 -11) . Certain peptides in nucleosomal histones are dominant autoepitopes and spontaneous priming to these occurs in preclinical lupus (12, 13) . These epitopes are cross-reactively recognized by autoimmune Th cells, as well as B cells of lupus, and they can be promiscuously presented in the context of diverse MHC class II (MHC II) 4 alleles, like "universal epitopes" (2, (12) (13) (14) . These unaltered, native peptide epitopes halt progression of lupus nephritis upon tolerization in high-dose soluble form and importantly for human therapy, the peptides are also effective in delaying/preventing lupus nephritis in subnanomolar doses (ϳ0.37 nM or 1 g), administered s.c. to lupus-prone SNF 1 mice (2, 3, 15) . This dose is 300-to 1000-fold less than peptides from other nucleoproteins or unrelated peptides from Ig V regions (CDR) that are being tried as therapeutic agents (4, 5, 16, 17) .
Among nucleosomal histone epitopes, H4 71-94 is highly potent in low-dose tolerance therapy, because it cross-reactively suppresses autoimmunity to other pathogenic epitopes and whole nucleosomes (2, 3) . Moreover, H4 71-94 also can suppress lupus via nasal tolerance (18) . Importantly, H4 71-94 also binds strongly to common HLA-DR alleles. T cells reactive to this epitope can be detected in almost all lupus patients, as well as SNF 1 and BWF 1 mice (2, 12, 13, 19, 20) .
The mechanism of the decades-old phenomenon of low-dose tolerance or "immunologic paralysis" (21-23) was unknown and even recent mechanistic studies (24) have dealt with tolerance in naive animals to foreign Ags. In lupus, we are studying low-dose tolerance in an immune system that is already primed spontaneously to high doses of the same nucleosomal autoepitope that is ubiquitous. Moreover, numerous traits for disease susceptibility were intact in the immune system of the spontaneous systemic lupus erythematosus model studied here. The complex cellular interactions were not curtailed or modified from birth by any transgenic or knockout approaches, nor have we added any exogenous TGF-␤ to help augment tolerance (24) because that might be detrimental in the presence of excessive IL-6 production in lupus (25, 26) . Indeed, we were surprised that therapeutic tolerance with H4 71-94 peptide could be achieved in the face of complex lupus traits like intrinsic hyperactivity of B cells, T cells, and dendritic cells (DC), particularly plasmacytoid DC (pDC) making excessive IFN-␣ (27) (28) (29) . Because low-dose tolerance with H4 71-94 peptide induces CD8
ϩ , and CD4 ϩ CD25 ϩ adaptive regulatory T (Treg) cell subsets that produce TGF-␤, and is highly potent in suppressing lupus nephritis (3), herein, we investigated the mechanism of Treg generation.
Materials and Methods

Mice
New Zealand Black and SWR mice were purchased from The Jackson Laboratory. Lupus-prone SNF 1 hybrids were bred and females were used, as approved by the animal care and use committee.
Peptides
All peptides were synthesized by F-moc chemistry and their purity was checked by amino acid analysis by the manufacturer (Chiron Mimotopes).
Tolerance induction with very low doses of peptides
For low-dose tolerance studies, serologically autoimmune, but prenephritic, 12-wk-old SNF 1 females (nine mice per group) were injected s.c. three times with H4 71-94 peptide (1 g/mouse) in PBS every 2 wk. The control group received only PBS. The mice were monitored weekly for proteinurea using Albustix (VWR Scientific).
Autoantibody quantitation
IgG class autoantibodies to ssDNA, dsDNA, histone, and nucleosome (histone-DNA complex) were measured by ELISA (7, 30) . Subclasses of IgG autoantibodies were detected by ELISA using alkaline phosphatase-conjugated anti-mouse IgG1, IgG2a, IgG2b, and IgG3 (Southern Biotechnology Associates). One month after adoptive transfer of pDC or non-pDC, recipient SNF 1 mice (at 5.5 mo and 2 wk of age), with or without acceleration of disease as the case might be, were bled for autoantibody measurement.
Cell isolation
Total, CD4 ϩ , and CD8 ϩ T cells from spleens were purified by using appropriate MACS isolation kits using magnetic bead-conjugated Abs specific to each Ag. CD4 ϩ CD25 ϩ T cells were purified by a mouse regulatory T cell isolation kit according to the manufacturer (Miltenyi Biotec). For DC isolation, spleens were injected with DMEM containing 1 mg/ml collagenase (Worthington Biomedical) and 50 g/ml DNase (Roche Applied Science) for digestion at 37°C for 45 min and then followed by washes in EDTA-containing buffer to prevent clumping as described (31) . CD11c ϩ DC, B cells, and macrophages were purified by using magnetic bead-conjugated Abs specific to CD11c, CD19, and CD11b, respectively. pDCs and non-pDCs were isolated by using the pDC isolation kit, according to the manufacturer (Miltenyi Biotec). Purity of all isolated cell subsets was Ͼ80 -90%.
Ex vivo presentation assay to track s.c. injected peptide
We injected SNF 1 mice s.c. with a high dose (300 g) of H4 71-94 peptide, following which we isolated DCs and B cells from their spleens at different time points between 6 and 48 h. The splenic DC or B cells were then cocultured with a highly sensitive T cell hybridoma, 102, which can detect H4 71-94 in attomole concentration (30) . IL-2 production by T hybridomas was measured in culture supernatants. No exogenous peptide was added to cultures.
In vitro stimulation of purified DCs
We isolated DCs from low-dose H4 71-94 -tolerized or PBS-treated mice and stimulated DC or DC subsets (3 ϫ 10 5 cells/well of 96-well plates) with nucleosomes (10 -50 g/ml), LPS (5-1000 ng/ml) from Sigma-Aldrich, phosphorothioate CpG oligonucleotides 1585 (0.5-10 g/ml) from Oligos Etc., or poly (I:C) (5-100 g/ml) from InvivoGen, in 10% FBS containing DMEM for 48 or 90 h. For inhibition of TLRs, we stimulated purified DC or DC subsets (3 ϫ 10 5 cells/well) from H4 71-94 -tolerized or PBStreated SNF 1 mice with nucleosomes in the presence or absence of 0 -30 M TLR9 inhibitor (5Ј-TCCTGGAGGGGTTGT-3Ј), TLR7 inhibitor (5Ј-TGCTTGCAAGCTTGCAAGCA-3Ј) from Oligos Etc., or chloroquine from InvivoGen, for 48 or 90 h (32) . We analyzed amounts of IFN-␣, IL-6, IL-12p70, IL-17, IL-23p19, and TGF-␤ in culture supernatants by ELISA.
Adoptive transfer
To determine their ability to inhibit accelerated lupus nephritis, DC, DC subsets (pDC and non-PDC), or B cells were isolated by MACS from 3-mo-old donor SNF 1 mice 24 h after s.c. injection with H4 71-94 (300 g/mouse) or PBS, and then immediately injected (1 ϫ 10 6 cells I.V.) into 3-mo-old SNF 1 , three times, at 2-wk intervals. One week later, the recipient mice were immunized with a lupus-accelerating nucleosomal peptide, H1Ј , in CFA. The animals were monitored for nephritis, survival, and IgG autoantibody levels for 5 mo after final adoptive transfer.
To test the immunological consequences of transferring DCs or B cells in recipient mice, another batch of 3-mo-old SNF 1 mice (five per group) were treated as above with or without immunization with H1Ј in CFA. Ten days after the third transfer (1 ϫ 10 6 cells/mouse for each transfer), these short-term batches of mice were sacrificed for analysis of autoimmune T and B cells and Treg cells using ELISPOT and/or ELISA for cytokines and IgG autoantibodies.
Immunohistochemistry
One-half of each kidney from tolerized or control mice was fixed in 10% formalin and paraffin embedded. Paraffin sections were used for immunohistochemical analysis of Th17 infiltration, as described (3).
ELISPOT assay
ELISPOT assay plates (Cellular Technology) were coated with capture Abs against IFN-␥ or IL-17 (BD Pharmingen) in PBS at 4°C overnight. Splenic T cells (1 ϫ 10 6 ) from treated mice were cultured with irradiated (3000 rad) splenic APC (B cells, macrophages, and DC) from 1-mo-old SNF 1 mice in the presence of peptides or PBS control. Cells were removed after 24 h of incubation for IFN-␥, or after 48 h for IL-17, and the reactions were visualized by addition of the individual anti-cytokine Ab biotin and subsequent alkaline phosphatase-conjugated streptavidin. Cytokine-expressing cells were detected by immunospot scanning and analysis (Cellular Technology). 
Suppression assay
Flow cytometry
For analyzing surface markers on DC, whole splenocyte populations were prepared by collagenase-DNase digestion followed by washes in EDTAcontaining buffer to prevent clumping as described (31) . To avoid unnecessary manipulations, further purifications were not done, but CD11c-FITC-and B220-allophycocyanin-positive cells were gated and analyzed after three-color staining of splenocytes. FITC-labeled anti-CD11c Ab, PElabeled anti-MHC II (M5/114.15.2), anti-CD83, anti-CD80, anti-CD86, anti-CD40, allophycocyanin-labeled anti-B220 Ab, and isotype controls were obtained from BD Biosciences; PE-labeled anti-CD205 Ab was obtained from Cedarlane Laboratories. PE-conjugated Ab to TGF-␤ from IQ products (Biotest Diagnostic) was used for intracellular staining. For intracellular staining of Th17 cells, splenocytes from H4 71-94 -tolerized or PBStreated SNF 1 mice were cultured for 48 h with H4 71-94 or nucleosomes and then Golgi Stop (eBioscience) was added to cultures 12 h before cell staining. We also stimulated splenocytes from H4 71-94 -tolerized or PBS-treated SNF 1 mice with PMA (50 ng/ml; Sigma-Aldrich) and ionomycin (1 nM; Calbiochem) for 4 -5 h and then Golgi Stop was added during last 2 h, as described (25) . Cells were then stained with CD4-FITC, fixed, and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences), and were then stained with IL-17-PE (BD Biosciences). 
CFSE-based cell proliferation assays
Real-time RT-PCR
Ten days after the third injection of H4 71-94 (1 g) in a low-dose tolerance regimen, we measured cytokine and indoleamine 2,3 dioxygenase (IDO) mRNAs by real-time PCR in whole DCs, or subsets (pDCs and non-pDCs) from H4 71-94 -tolerized or PBS control mice without further stimulation. To measure expression of cytokine mRNAs, total RNAs from DC or DC subsets from low-dose peptide-tolerized or PBS control mice were isolated by the RNeasy kit (Qiagen) and then cDNA was synthesized using a highcapacity cDNA archive kit (Applied Biosystems). Expressions of IFN-␣, IL-6, IL-10, IL-12, TGF-␤, and IDO mRNA were measured using Assayson-Demand gene expression products and TaqMan Universal PCR master mix (Applied Biosystems). GAPDH was used as an endogenous reference. We analyzed data as described (3) using ABI 7700 Sequence Detection system software (Applied Biosystems).
Statistical analysis
The log-rank and the Student two-tailed t tests were used. Results are expressed as the mean Ϯ SEM, unless noted otherwise.
Results
Fate of injected nucleosomal histone peptide
Because s.c. injection of low-dose peptide generated potent Treg in spleen (3), we investigated which APC were involved. Within 24 h of s.c. injection of H4 71-94 , both splenic DCs and B cells stimulated a highly sensitive, H4 71-94 -specific T cell hybridoma without further addition of the exogenous peptide (Fig. 1A) . The DCs presented captured peptides more efficiently. The APCs of control PBS-treated animals stimulated weakly, probably presenting endogenously acquired autoantigens (12, 30) . DC and B cells from the draining lymph nodes did not stimulate the cognate T cell hybridoma (data not shown).
The DCs, but not B cells, of the H4 71-94 -tolerized animals blocked lupus acceleration
Adoptive transfer of the splenic DCs of H4 71-94 -tolerized animals delayed the onset of accelerated lupus nephritis in H1Ј 22-42 -immunized SNF 1 mice (Fig. 1B ) and prolonged survival (Fig. 1C) . In the nephritis acceleration assay, young SNF 1 mice immunized with another nucleosomal epitope, H1Ј in adjuvant develop severe nephritis and produce high level of autoantibodies much more rapidly, as described (3, 30) . Between 8 and 10 wk after final (third) adoptive transfer of H4 71-94 -tolerized DC, only 20% of recipient mice had severe nephritis, whereas 80% of mice receiving PBStreated control DC had severe nephritis ( p Ͻ 0.01). Between 16 to 20 wk after final transfer of H4 71-94 -tolerized DCs, 100% of recipient mice had survived, whereas 50% of mice receiving control DCs were dead ( p Ͻ 0.01). Transfer of H4 71-94 -tolerized animal B cells had no significant effect (Fig. 1, B and C) .
The DC and subsets from H4 71-94 -tolerized animals diminished IgG autoantibodies and T cell responses to nucleosomes
Adoptive transfer of H4 71-94 -tolerized DCs reduced the levels of the pathogenic (CЈ fixing, inflammatory Fc␥R binding) subclass of IgG2a autoantibodies to dsDNA, ssDNA, nucleosomes, and histones by 42, 26, 54, and 64%, respectively ( p Ͻ 0.001-Ͻ0.05, Fig.  1D ), but transfer of the B cells of the H4 71-94 -tolerized animals did not, except for histones. Adoptive transfer of the DCs of H4 71-94 -tolerized animals diminished recipient T cell responses to nucleosomes up to 70%, as compared with control recipients (Fig. 1E , p Ͻ 0.01), whereas transfer of H4 71-94 -tolerized B cells did not (Fig. 1E, p Ͼ 0.05) .
We further isolated subsets from H4 71-94 tolerized animal's DCs into plasmacytoid DC (pDC) and non-pDC for adoptive transfer. Ten days after the third transfer, we analyzed the levels of pathogenic IgG autoantibodies in serum and IFN-␥ response to nucleosomal autoantigen by T cells of recipient mice. Both subsets of H4 71-94 tolerized DCs reduced pathogenic IgG2a and IgG2b subclasses of autoantibodies in recipients ( Fig. 2A, p Ͻ 0.02) . Adoptive transfer of H4 71-94 -tolerized pDC, but not non-pDC, markedly suppressed (up to 85%) the IFN-␥ response of T cells of recipient mice on challenge with nucleosomes in vitro as compared with transfer of the pDC of the PBS-treated animals (Fig. 2B , p Ͻ 0.001-0.05). Thus, during the 5-mo observation, only three transfers of DCs from H4 71-94 -tolerized mice could delay the incidence of severe nephritis, suppress responses of lupus T cells to nucleosomes, and reduce pathogenic IgG2a autoantibodies.
Transfer of the pDCs of H4 71-94 -tolerized animals caused increased TGF-␤ and decreased IL-17 production by recipient T cells
We observed significantly increased amount of TGF-␤ in culture of T cells in splenocytes from recipients of H4 71-94 -tolerized pDCs (but not non-pDCs), in response to nucleosomes, as compared with that of PBS-treated pDCs (Fig. 3A) . There were no significant differences among the recipient groups of DC subsets for IL-10 ( Fig. 3B) or IL-4 production (data not shown). In contrast, IL-17 levels in nucleosome-stimulated cultures of splenocytes from SNF 1 recipients of the pDC (but not non-pDC) of H4 71-94 -tolerized animals were markedly reduced, as compared with recipients of PBS-treated animal pDC (Fig. 3C , p Ͻ 0.001).
Unmanipulated lupus-prone SNF 1 mice had markedly increased Th17 response to nucleosome autoantigens, as compared with nonautoimmune, SWR, or C57BL/6 mice (Fig. 3D) , and low-dose tolerance with H4 71-94 (1 g) markedly reduced their IL-17 production in response to nucleosomes by ELISPOT (Fig. 3E) . Flow cytometry also showed significantly reduced Th17 cells upon autoantigen stimulation in tolerized SNF 1 mice (Table I) . We could not detect any significant Th17 cells in SNF 1 mice without autoantigen stimulation, even upon ionomycin and PMA stimulation (data not shown).
We observed infiltration of Th17 cells in kidneys from controltreated mice by immunohistochemistry, whereas no such infiltrates in kidneys from H4 71-94 -tolerized mice, indicating that low-dose tolerance inhibited expansion and migration of activated Th17 cells to target organs (Fig. 3F) .
Low-dose tolerance with H4 71-94 increases TGF-␤, but decreases IL-6 production by DCs
Because adoptive transfer of tolerized pDC caused TGF-␤ production by T cells of recipients, we analyzed the DCs themselves. Without further stimulation, we observed significant increases of TGF-␤ and IL-10 mRNA in whole DCs from H4 71-94 -tolerized mice, as compared with controls (Fig. 4A) , but no significant change in IDO mRNA ( p Ͼ 0.05). In DC subsets, TGF-␤ mRNA in H4 71-94 -tolerized pDCs was 4-fold higher than PBS control pDCs (Fig. 4A , p Ͻ 0.001), but no significant differences were seen in non-pDCs (Fig. 4A) . Isolated pDC subsets die overnight in culture unlike in vivo adoptive transfer experiments or assays done with them immediately ex vivo. Therefore, any experiment described below that required culturing for several days could be done only with the whole DC population. Nevertheless, the results in Figs. 2B, 3A, 4A, and 5A show that the tolerogenic effects were mainly due to pDC.
The low-dose tolerance regimen with H4 71-94 also increased production of TGF-␤ by DCs on stimulation in vitro with poly (I:C), CpG, or nucleosomes, but not LPS (Fig. 4B , p Ͻ 0.001-Ͻ0.01). In contrast, low-dose H4 71-94 tolerance markedly reduced IL-6 production by DCs stimulated by same agents (Fig. 4C, 
TLR9 is involved in production of TGF-␤ from DCs in low-dose tolerance
As major lupus autoantigens, nucleosomes, and small nuclear ribonucleoprotein contain DNA and RNA, we analyzed whether TLRs were involved. We isolated DCs from low-dose H4 71-94 -tolerized or PBS-treated animals, and stimulated DCs with nucleosomes in the presence of TLR9 inhibitor or TLR7 inhibitors. TLR9-specific inhibitor decreased TGF-␤ production by H4 71-94 -tolerized DCs on stimulation with nucleosomes in vitro (Fig. 4D , p Ͻ 0.01-0.05), but TLR7 inhibitor did not ( p Ͼ 0.05, data not shown).
In contrast, the TLR9 inhibitor increased IL-6 production by H4 71-94 -tolerized DCs on stimulation with nucleosomes in vitro (Fig. 4D) . The inhibitor was not toxic because the IL-6-enhancing effect was seen even at high doses that were required to inhibit large number of DCs (0.3-1 ϫ 10 6 cells/well).
pDCs of H4 71-94 -tolerized animals have a tolerogenic phenotype
As shown in Table II , among the pDC of H4 71-94 -tolerized mice, the percentage of CD40 ϩ cells and their mean and median fluorescence intensity (MFI) were decreased by 73, 32, and 44%, respectively ( p Ͻ 0.01, Ͻ0.05, Ͻ0.05), and the percent and MFI of CD80 were decreased by 29 and 20%, respectively ( p Ͻ 0.05). Slight increases of CD86 and MHC II on H4 71-94 -tolerized pDC were not significant (1.14-and 1.02-fold, respectively, p Ͼ 0.05), but MFI of CD86 was significantly reduced by 29% ( p Ͻ 0.05).
Percentage of CD83
ϩ cells (mature DC marker) was decreased by 18% and its mean fluorescence was decreased by 60% on H4 71-94 -tolerized pDC ( p Ͻ 0.05), but CD205, a tolerogenic DC receptor (33, 34) was not significantly changed ( p Ͼ 0.05). Median fluorescence of PD-L1, which inhibits T cells (35) , was increased on H4 71-94 -tolerized pDC by 18%, as compared with control ( p Ͻ 0.05). The changes in surface markers are not as striking as the functional changes in the pDC of tolerized animals, probably because the steps needed to isolate DCs may change their surface markers quickly to a relatively more activated phenotype.
Intracellular staining for TGF-␤ (data not shown in table) was consistent with results in Fig. 4 . The whole DC of H4 71-94 -tolerized animals had increased TGF-␤ ϩ cells (45.20 Ϯ 3%, p Ͻ 0.01), as compared with PBS-treated controls (27.35 Ϯ 2), and the percentages of TGF-␤ ϩ cells were also increased 1.25-fold in pDC and 1.81-fold in non-pDC subsets from low-dose H4 71-94 -tolerized mice ( p Ͻ 0.01). Furthermore, mean and median fluorescence of TGF-␤ ϩ pDC by low-dose H4 71-94 tolerance were 2.5-and 1.96-fold higher than those of non-pDC (all p Ͻ 0.05).
Transfer of H4 71-94 -tolerized pDC augmented suppressive function of both CD4
ϩ CD25 ϩ and CD8 ϩ Treg cells in recipients Ten days after final (third) transfer of the DC subsets of low-dose H4 71-94 -tolerized or PBS-treated animals, we isolated both CD4 ϩ CD25 ϩ and CD8 ϩ T cells from recipient mice and then cocultured the T cells with T cells from 5.5-mo-old unmanipulated SNF 1 mice, in the presence of nucleosomes. As compared with CD4 ϩ CD25 ϩ and CD8 ϩ T cells from recipients of PBS-treated animal pDC (Fig. 5A, p Ͻ 0.001) , both of those cell subsets from recipients of H4 71-94 -tolerized pDC had up to 2.2-fold higher suppressing ability of the IFN-␥ response to nucleosomes at 1:4 ratio (Treg cells-target lupus T cells, optimal ratio as titrated in Fig. 5B) . However, adoptive transfer of H4 71-94 -tolerized non-pDC did not increase suppressive function (Fig. 5A, p Ͼ have class I epitope motifs, indicating that CD8 ϩ Treg cells require additional factors to expand in vitro cultures.
Discussion
We found that low-dose tolerance with the dominant H4 71-94 peptide epitope could bring about a tolerogenic phenotype in a substantial fraction of pDC, which then induced Treg cells and suppressed Th17 inflammatory cells. The therapeutic benefit of H4 71-94 peptide is further augmented by degeneracy of lupus autoimmune system for nucleosomal epitopes: a single peptide epitope from a histone in the nucleosome can be recognized by multiple autoimmune T cells of lupus with diverse receptors, and conversely, a single autoimmune T cell can recognize structurally different histone peptides (12, 14) . Thus, a single peptide epitope can tolerize a spectrum of autoimmune Th cells and tolerizing one set of Th cells deprives help for multiple autoimmune B cells of lupus (tolerance spreading) (2, 3) . Our studies indicate that s.c.-injected peptides spread systemically and were captured by splenic APC (DC). In another system, a tolerizing peptide injected s.c. spread through the body 16 times faster than an immunogenic peptide (36) . We found that B cells are not involved here in induction of tolerance, which is in contrast to some studies (37) but consistent with others (38) . Therefore, we focused on DC subsets. Both pDC and non-pDC from H4 71-94 -tolerized SNF 1 mice on adoptive transfer reduced IgG autoantibodies significantly ( p Ͻ 0.05-Ͻ0.001), but only pDC could suppress IFN-␥ responses of lupus-prone recipient T cells to autoantigens, expand Treg cells with increased TGF-␤ production, and increase survival.
Our results indicate that H4 71-94 peptide in low-dose tolerance causes DCs, especially pDCs to produce increased amount of TGF-␤, which is a critical factor for generation of Treg cells (39, 40) . Although pDCs produce large amounts of type I IFNs in lupus (28), IFN-␣ mRNA levels were not changed by therapy. Also, we did not observe significant difference in IDO mRNA expression by low-dose tolerance, in contrast to other systems (41) .
However, DCs from H4 71-94 -tolerized mice upon stimulation by nucleosome or mitogens showed markedly suppressed production of IL-6. Ligation of TLRs on DCs stimulates production of IL-6, which overcomes CD4 ϩ CD25 ϩ Treg cell-mediated suppression leading to T cell activation in vivo (24 -26, 42) . Our studies show that DC from low-dose H4 71-94 -tolerized mice have an opposite phenotype with increased production of TGF-␤ and decreased IL-6 on stimulation with TLR ligands or the major autoantigen, nucleosomes; this tolerogenic phenotype was mediated by TLR9 binding of nucleosomal DNA. In accordance, TLR9 knockout lupus-prone MRL mice have a deficiency in Treg cells (43) .
As recently described, exogenously added IL-6, with TGF-␤, causes induction of Th17 cells that cause autoimmune tissue injury, and IL-6 inhibits the generation of foxp3 ϩ Treg cells induced by TGF-␤ (25, 26, 39, 40, 44) . We show here that low-dose peptide tolerance of lupus could simultaneously induce Treg cells and suppress Th17 cells by increasing TGF-␤ and decreasing IL-6 production by DC. However, IL-23p19 levels were not changed in cultures of DCs from H4 71-94 -tolerized mice. Th17 cells increased only in SNF 1 lupus mice after stimulation with nucleosomes or H4 71-94 , however, exogenously created polarizing cytokine conditions were not necessary. Moreover, PMA plus ionomycin stimulation alone could not bring out the splenic Th17 cells (data not shown). These results obtained with polyclonal peripheral T cells of nontransgenic, lupus-prone mice, in response to just one (albeit major) autoantigenic epitope, are notable because most Th 17 cells migrate to target organs in autoimmune disease (Fig. 3F) . The autoantigen-specific Th 17 response was decreased up to 10-fold in low-dose peptide-tolerized mice ( p Ͻ 0.001, Fig. 3 , Table I ). Lowdose H4 71-94 tolerance also prevented infiltration of Th17 cells in kidney (Fig. 3F) , but we could observe some linear staining in glomeruli from both control and peptide-tolerized mice, probably due to expression of IL-17Rs on kidney cells (45 Ϫ T cells and their expansion was described previously using TCR-transgenic cells with addition of a high amount of exogenous IL-2 and/or TGF-␤ (24, 40, 46, 47) . Our studies provide direct evidence for induction of autoantigen, specifically induced Treg cells by low-dose peptide tolerance in complex setting of spontaneous autoimmune disease without the addition of high-dose exogenous IL-2 that may rescue premalignant T cells, or of TGF-␤ that in presence of high IL-6 in lupus could induce inflammatory Th17 cells (24 -26) .
Another group induced CD4 ϩ CD25 ϩ Treg cells by continuous infusion of a model Ag in low doses using hemagglutinin-specific TCR-transgenic mouse system (48) . However, continuous infusion of peptide indefinitely is not practical in humans. In lupus nephritis, striking therapeutic effect is achieved with biweekly s.c. injection of nucleosomal peptide epitopes in very low dose (2, 3, 15) . In lupus patients, the most damaging side effects and morbidity occur from chronic life-long maintenance therapy with steroids and cytotoxic agents and, despite their use, flares and progression of renal disease occurs. Our therapy with H4 71-94 peptide has certain advantages: 1) it is an unaltered peptide ligand, being naturally occurring with evolutionarily conserved sequences, ubiquitous, expressed in the thymus during ontogeny (49), and not causing Th2 deviation (unlike altered peptide ligands) (50) , and therefore, not associated with anaphylactic/allergic reactions; 2) it is effective at low doses and by s.c. administration in an animal model of lupus; 3) it generates long-lasting, Ag-specific regulatory T cells that suppress pathogenic autoantibody production and lupus nephritis; 4) it is cross-reactive, inducing "tolerance spreading" to other pathogenic T cell autoepitopes of lupus, but not to exogenous Ags; and 5) it is recognized by autoimmune T cells of all lupus patients tested irrespective of their HLA type.
Our peptide therapy might be most suitable for maintaining lupus patients after remission has been induced by more toxic or global immunosuppressive agents. Even apparently healthy subjects and family members of lupus patients, who might be at risk of developing lupus (as predicted by genetic and biomarkers), might benefit from the peptide therapy, because it repairs a defect in Treg cell deficiency in lupus (51) (52) (53) . Importantly, these peptides appear to be effective even when the autoimmune disease is already established and restores normal lifespan in lupus mice (2, 3) .
